ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global New Molecular Entity (NME) Drug Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-29A16091
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global New Molecular Entity NME Drug Market Research Report 2023
BUY CHAPTERS

Global New Molecular Entity (NME) Drug Market Research Report 2024

Code: QYRE-Auto-29A16091
Report
August 2024
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
UCB
Otsuka Pharmaceutical
Eli Lilly
Genentech Inc
Eisai Co Ltd
Biogen
Menarini Group
GSK
CHEST
Pfizer Inc
ACADIA Pharmaceuticals
Incyte
Pharming
LEO Pharma
Novartis
Argenx
Takeda
AbbVie
Sanofi
Travere
Reata
Cidara
Melinta
Bayer Hlthcare
Immumnocore

New Molecular Entity (NME) Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

New Molecular Entity (NME) Drug Market

New Molecular Entity (NME) Drug Market

New Molecular Entity refers to a chemical structure with certain biological activity. Due to its weak activity, low selectivity, poor absorption, or high toxicity, it cannot be directly used as medicine. However, as a new structural type and clue substance, through structural transformation and modification, drugs with excellent pharmacological effects can be obtained.
The global New Molecular Entity (NME) Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for New Molecular Entity (NME) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding New Molecular Entity (NME) Drug.

Report Scope

The New Molecular Entity (NME) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global New Molecular Entity (NME) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the New Molecular Entity (NME) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of New Molecular Entity (NME) Drug Market Report

Report Metric Details
Report Name New Molecular Entity (NME) Drug Market
CAGR 5%
Segment by Type
  • Antibody
  • Polypeptide
  • Small Molecule Drug
  • Other
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company UCB, Otsuka Pharmaceutical, Eli Lilly, Genentech, Eisai, Biogen, Menarini Group, GSK, Chest, Travere, Reata, Pfizer, Acadia Pharmaceuticals, Incyte, Cidara, Melinta, Pharming, LEO Pharma, Novartis, Argenx, Takeda, AbbVie, Bayer Hlthcare, Sanofi, Immumnocore
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of New Molecular Entity (NME) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the New Molecular Entity (NME) Drug Market report?

Ans: The main players in the New Molecular Entity (NME) Drug Market are UCB, Otsuka Pharmaceutical, Eli Lilly, Genentech, Eisai, Biogen, Menarini Group, GSK, Chest, Travere, Reata, Pfizer, Acadia Pharmaceuticals, Incyte, Cidara, Melinta, Pharming, LEO Pharma, Novartis, Argenx, Takeda, AbbVie, Bayer Hlthcare, Sanofi, Immumnocore

What are the Application segmentation covered in the New Molecular Entity (NME) Drug Market report?

Ans: The Applications covered in the New Molecular Entity (NME) Drug Market report are Hospital, Clinic

What are the Type segmentation covered in the New Molecular Entity (NME) Drug Market report?

Ans: The Types covered in the New Molecular Entity (NME) Drug Market report are Antibody, Polypeptide, Small Molecule Drug, Other

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global New Molecular Entity (NME) Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antibody
1.2.3 Polypeptide
1.2.4 Small Molecule Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global New Molecular Entity (NME) Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global New Molecular Entity (NME) Drug Market Perspective (2019-2030)
2.2 New Molecular Entity (NME) Drug Growth Trends by Region
2.2.1 Global New Molecular Entity (NME) Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 New Molecular Entity (NME) Drug Historic Market Size by Region (2019-2024)
2.2.3 New Molecular Entity (NME) Drug Forecasted Market Size by Region (2025-2030)
2.3 New Molecular Entity (NME) Drug Market Dynamics
2.3.1 New Molecular Entity (NME) Drug Industry Trends
2.3.2 New Molecular Entity (NME) Drug Market Drivers
2.3.3 New Molecular Entity (NME) Drug Market Challenges
2.3.4 New Molecular Entity (NME) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top New Molecular Entity (NME) Drug Players by Revenue
3.1.1 Global Top New Molecular Entity (NME) Drug Players by Revenue (2019-2024)
3.1.2 Global New Molecular Entity (NME) Drug Revenue Market Share by Players (2019-2024)
3.2 Global New Molecular Entity (NME) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by New Molecular Entity (NME) Drug Revenue
3.4 Global New Molecular Entity (NME) Drug Market Concentration Ratio
3.4.1 Global New Molecular Entity (NME) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by New Molecular Entity (NME) Drug Revenue in 2023
3.5 New Molecular Entity (NME) Drug Key Players Head office and Area Served
3.6 Key Players New Molecular Entity (NME) Drug Product Solution and Service
3.7 Date of Enter into New Molecular Entity (NME) Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 New Molecular Entity (NME) Drug Breakdown Data by Type
4.1 Global New Molecular Entity (NME) Drug Historic Market Size by Type (2019-2024)
4.2 Global New Molecular Entity (NME) Drug Forecasted Market Size by Type (2025-2030)
5 New Molecular Entity (NME) Drug Breakdown Data by Application
5.1 Global New Molecular Entity (NME) Drug Historic Market Size by Application (2019-2024)
5.2 Global New Molecular Entity (NME) Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America New Molecular Entity (NME) Drug Market Size (2019-2030)
6.2 North America New Molecular Entity (NME) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America New Molecular Entity (NME) Drug Market Size by Country (2019-2024)
6.4 North America New Molecular Entity (NME) Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe New Molecular Entity (NME) Drug Market Size (2019-2030)
7.2 Europe New Molecular Entity (NME) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe New Molecular Entity (NME) Drug Market Size by Country (2019-2024)
7.4 Europe New Molecular Entity (NME) Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific New Molecular Entity (NME) Drug Market Size (2019-2030)
8.2 Asia-Pacific New Molecular Entity (NME) Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America New Molecular Entity (NME) Drug Market Size (2019-2030)
9.2 Latin America New Molecular Entity (NME) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America New Molecular Entity (NME) Drug Market Size by Country (2019-2024)
9.4 Latin America New Molecular Entity (NME) Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa New Molecular Entity (NME) Drug Market Size (2019-2030)
10.2 Middle East & Africa New Molecular Entity (NME) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 UCB
11.1.1 UCB Company Detail
11.1.2 UCB Business Overview
11.1.3 UCB New Molecular Entity (NME) Drug Introduction
11.1.4 UCB Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.1.5 UCB Recent Development
11.2 Otsuka Pharmaceutical
11.2.1 Otsuka Pharmaceutical Company Detail
11.2.2 Otsuka Pharmaceutical Business Overview
11.2.3 Otsuka Pharmaceutical New Molecular Entity (NME) Drug Introduction
11.2.4 Otsuka Pharmaceutical Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.2.5 Otsuka Pharmaceutical Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly New Molecular Entity (NME) Drug Introduction
11.3.4 Eli Lilly Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 Genentech
11.4.1 Genentech Company Detail
11.4.2 Genentech Business Overview
11.4.3 Genentech New Molecular Entity (NME) Drug Introduction
11.4.4 Genentech Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.4.5 Genentech Recent Development
11.5 Eisai
11.5.1 Eisai Company Detail
11.5.2 Eisai Business Overview
11.5.3 Eisai New Molecular Entity (NME) Drug Introduction
11.5.4 Eisai Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.5.5 Eisai Recent Development
11.6 Biogen
11.6.1 Biogen Company Detail
11.6.2 Biogen Business Overview
11.6.3 Biogen New Molecular Entity (NME) Drug Introduction
11.6.4 Biogen Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.6.5 Biogen Recent Development
11.7 Menarini Group
11.7.1 Menarini Group Company Detail
11.7.2 Menarini Group Business Overview
11.7.3 Menarini Group New Molecular Entity (NME) Drug Introduction
11.7.4 Menarini Group Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.7.5 Menarini Group Recent Development
11.8 GSK
11.8.1 GSK Company Detail
11.8.2 GSK Business Overview
11.8.3 GSK New Molecular Entity (NME) Drug Introduction
11.8.4 GSK Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.8.5 GSK Recent Development
11.9 Chest
11.9.1 Chest Company Detail
11.9.2 Chest Business Overview
11.9.3 Chest New Molecular Entity (NME) Drug Introduction
11.9.4 Chest Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.9.5 Chest Recent Development
11.10 Travere
11.10.1 Travere Company Detail
11.10.2 Travere Business Overview
11.10.3 Travere New Molecular Entity (NME) Drug Introduction
11.10.4 Travere Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.10.5 Travere Recent Development
11.11 Reata
11.11.1 Reata Company Detail
11.11.2 Reata Business Overview
11.11.3 Reata New Molecular Entity (NME) Drug Introduction
11.11.4 Reata Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.11.5 Reata Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer New Molecular Entity (NME) Drug Introduction
11.12.4 Pfizer Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.12.5 Pfizer Recent Development
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Detail
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals New Molecular Entity (NME) Drug Introduction
11.13.4 Acadia Pharmaceuticals Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.13.5 Acadia Pharmaceuticals Recent Development
11.14 Incyte
11.14.1 Incyte Company Detail
11.14.2 Incyte Business Overview
11.14.3 Incyte New Molecular Entity (NME) Drug Introduction
11.14.4 Incyte Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.14.5 Incyte Recent Development
11.15 Cidara
11.15.1 Cidara Company Detail
11.15.2 Cidara Business Overview
11.15.3 Cidara New Molecular Entity (NME) Drug Introduction
11.15.4 Cidara Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.15.5 Cidara Recent Development
11.16 Melinta
11.16.1 Melinta Company Detail
11.16.2 Melinta Business Overview
11.16.3 Melinta New Molecular Entity (NME) Drug Introduction
11.16.4 Melinta Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.16.5 Melinta Recent Development
11.17 Pharming
11.17.1 Pharming Company Detail
11.17.2 Pharming Business Overview
11.17.3 Pharming New Molecular Entity (NME) Drug Introduction
11.17.4 Pharming Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.17.5 Pharming Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Detail
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma New Molecular Entity (NME) Drug Introduction
11.18.4 LEO Pharma Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.18.5 LEO Pharma Recent Development
11.19 Novartis
11.19.1 Novartis Company Detail
11.19.2 Novartis Business Overview
11.19.3 Novartis New Molecular Entity (NME) Drug Introduction
11.19.4 Novartis Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.19.5 Novartis Recent Development
11.20 Argenx
11.20.1 Argenx Company Detail
11.20.2 Argenx Business Overview
11.20.3 Argenx New Molecular Entity (NME) Drug Introduction
11.20.4 Argenx Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.20.5 Argenx Recent Development
11.21 Takeda
11.21.1 Takeda Company Detail
11.21.2 Takeda Business Overview
11.21.3 Takeda New Molecular Entity (NME) Drug Introduction
11.21.4 Takeda Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.21.5 Takeda Recent Development
11.22 AbbVie
11.22.1 AbbVie Company Detail
11.22.2 AbbVie Business Overview
11.22.3 AbbVie New Molecular Entity (NME) Drug Introduction
11.22.4 AbbVie Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.22.5 AbbVie Recent Development
11.23 Bayer Hlthcare
11.23.1 Bayer Hlthcare Company Detail
11.23.2 Bayer Hlthcare Business Overview
11.23.3 Bayer Hlthcare New Molecular Entity (NME) Drug Introduction
11.23.4 Bayer Hlthcare Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.23.5 Bayer Hlthcare Recent Development
11.24 Sanofi
11.24.1 Sanofi Company Detail
11.24.2 Sanofi Business Overview
11.24.3 Sanofi New Molecular Entity (NME) Drug Introduction
11.24.4 Sanofi Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.24.5 Sanofi Recent Development
11.25 Immumnocore
11.25.1 Immumnocore Company Detail
11.25.2 Immumnocore Business Overview
11.25.3 Immumnocore New Molecular Entity (NME) Drug Introduction
11.25.4 Immumnocore Revenue in New Molecular Entity (NME) Drug Business (2019-2024)
11.25.5 Immumnocore Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
UCB
Otsuka Pharmaceutical
Eli Lilly
Genentech Inc
Eisai Co Ltd
Biogen
Menarini Group
GSK
CHEST
Pfizer Inc
ACADIA Pharmaceuticals
Incyte
Pharming
LEO Pharma
Novartis
Argenx
Takeda
AbbVie
Sanofi
Travere
Reata
Cidara
Melinta
Bayer Hlthcare
Immumnocore
List of Tables
    Table 1. Global New Molecular Entity (NME) Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Antibody
    Table 3. Key Players of Polypeptide
    Table 4. Key Players of Small Molecule Drug
    Table 5. Key Players of Other
    Table 6. Global New Molecular Entity (NME) Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global New Molecular Entity (NME) Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global New Molecular Entity (NME) Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global New Molecular Entity (NME) Drug Market Share by Region (2019-2024)
    Table 10. Global New Molecular Entity (NME) Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global New Molecular Entity (NME) Drug Market Share by Region (2025-2030)
    Table 12. New Molecular Entity (NME) Drug Market Trends
    Table 13. New Molecular Entity (NME) Drug Market Drivers
    Table 14. New Molecular Entity (NME) Drug Market Challenges
    Table 15. New Molecular Entity (NME) Drug Market Restraints
    Table 16. Global New Molecular Entity (NME) Drug Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global New Molecular Entity (NME) Drug Market Share by Players (2019-2024)
    Table 18. Global Top New Molecular Entity (NME) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Molecular Entity (NME) Drug as of 2023)
    Table 19. Ranking of Global Top New Molecular Entity (NME) Drug Companies by Revenue (US$ Million) in 2023
    Table 20. Global 5 Largest Players Market Share by New Molecular Entity (NME) Drug Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players New Molecular Entity (NME) Drug Product Solution and Service
    Table 23. Date of Enter into New Molecular Entity (NME) Drug Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global New Molecular Entity (NME) Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global New Molecular Entity (NME) Drug Revenue Market Share by Type (2019-2024)
    Table 27. Global New Molecular Entity (NME) Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global New Molecular Entity (NME) Drug Revenue Market Share by Type (2025-2030)
    Table 29. Global New Molecular Entity (NME) Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global New Molecular Entity (NME) Drug Revenue Market Share by Application (2019-2024)
    Table 31. Global New Molecular Entity (NME) Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global New Molecular Entity (NME) Drug Revenue Market Share by Application (2025-2030)
    Table 33. North America New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 34. North America New Molecular Entity (NME) Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 35. North America New Molecular Entity (NME) Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 36. Europe New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. Europe New Molecular Entity (NME) Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 38. Europe New Molecular Entity (NME) Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Asia-Pacific New Molecular Entity (NME) Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 40. Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 41. Asia-Pacific New Molecular Entity (NME) Drug Market Size by Region (2025-2030) & (US$ Million)
    Table 42. Latin America New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Latin America New Molecular Entity (NME) Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Latin America New Molecular Entity (NME) Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa New Molecular Entity (NME) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Middle East & Africa New Molecular Entity (NME) Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 48. UCB Company Detail
    Table 49. UCB Business Overview
    Table 50. UCB New Molecular Entity (NME) Drug Product
    Table 51. UCB Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 52. UCB Recent Development
    Table 53. Otsuka Pharmaceutical Company Detail
    Table 54. Otsuka Pharmaceutical Business Overview
    Table 55. Otsuka Pharmaceutical New Molecular Entity (NME) Drug Product
    Table 56. Otsuka Pharmaceutical Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 57. Otsuka Pharmaceutical Recent Development
    Table 58. Eli Lilly Company Detail
    Table 59. Eli Lilly Business Overview
    Table 60. Eli Lilly New Molecular Entity (NME) Drug Product
    Table 61. Eli Lilly Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 62. Eli Lilly Recent Development
    Table 63. Genentech Company Detail
    Table 64. Genentech Business Overview
    Table 65. Genentech New Molecular Entity (NME) Drug Product
    Table 66. Genentech Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 67. Genentech Recent Development
    Table 68. Eisai Company Detail
    Table 69. Eisai Business Overview
    Table 70. Eisai New Molecular Entity (NME) Drug Product
    Table 71. Eisai Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 72. Eisai Recent Development
    Table 73. Biogen Company Detail
    Table 74. Biogen Business Overview
    Table 75. Biogen New Molecular Entity (NME) Drug Product
    Table 76. Biogen Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 77. Biogen Recent Development
    Table 78. Menarini Group Company Detail
    Table 79. Menarini Group Business Overview
    Table 80. Menarini Group New Molecular Entity (NME) Drug Product
    Table 81. Menarini Group Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 82. Menarini Group Recent Development
    Table 83. GSK Company Detail
    Table 84. GSK Business Overview
    Table 85. GSK New Molecular Entity (NME) Drug Product
    Table 86. GSK Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 87. GSK Recent Development
    Table 88. Chest Company Detail
    Table 89. Chest Business Overview
    Table 90. Chest New Molecular Entity (NME) Drug Product
    Table 91. Chest Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 92. Chest Recent Development
    Table 93. Travere Company Detail
    Table 94. Travere Business Overview
    Table 95. Travere New Molecular Entity (NME) Drug Product
    Table 96. Travere Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 97. Travere Recent Development
    Table 98. Reata Company Detail
    Table 99. Reata Business Overview
    Table 100. Reata New Molecular Entity (NME) Drug Product
    Table 101. Reata Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 102. Reata Recent Development
    Table 103. Pfizer Company Detail
    Table 104. Pfizer Business Overview
    Table 105. Pfizer New Molecular Entity (NME) Drug Product
    Table 106. Pfizer Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 107. Pfizer Recent Development
    Table 108. Acadia Pharmaceuticals Company Detail
    Table 109. Acadia Pharmaceuticals Business Overview
    Table 110. Acadia Pharmaceuticals New Molecular Entity (NME) Drug Product
    Table 111. Acadia Pharmaceuticals Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 112. Acadia Pharmaceuticals Recent Development
    Table 113. Incyte Company Detail
    Table 114. Incyte Business Overview
    Table 115. Incyte New Molecular Entity (NME) Drug Product
    Table 116. Incyte Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 117. Incyte Recent Development
    Table 118. Cidara Company Detail
    Table 119. Cidara Business Overview
    Table 120. Cidara New Molecular Entity (NME) Drug Product
    Table 121. Cidara Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 122. Cidara Recent Development
    Table 123. Melinta Company Detail
    Table 124. Melinta Business Overview
    Table 125. Melinta New Molecular Entity (NME) Drug Product
    Table 126. Melinta Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 127. Melinta Recent Development
    Table 128. Pharming Company Detail
    Table 129. Pharming Business Overview
    Table 130. Pharming New Molecular Entity (NME) Drug Product
    Table 131. Pharming Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 132. Pharming Recent Development
    Table 133. LEO Pharma Company Detail
    Table 134. LEO Pharma Business Overview
    Table 135. LEO Pharma New Molecular Entity (NME) Drug Product
    Table 136. LEO Pharma Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 137. LEO Pharma Recent Development
    Table 138. Novartis Company Detail
    Table 139. Novartis Business Overview
    Table 140. Novartis New Molecular Entity (NME) Drug Product
    Table 141. Novartis Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 142. Novartis Recent Development
    Table 143. Argenx Company Detail
    Table 144. Argenx Business Overview
    Table 145. Argenx New Molecular Entity (NME) Drug Product
    Table 146. Argenx Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 147. Argenx Recent Development
    Table 148. Takeda Company Detail
    Table 149. Takeda Business Overview
    Table 150. Takeda New Molecular Entity (NME) Drug Product
    Table 151. Takeda Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 152. Takeda Recent Development
    Table 153. AbbVie Company Detail
    Table 154. AbbVie Business Overview
    Table 155. AbbVie New Molecular Entity (NME) Drug Product
    Table 156. AbbVie Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 157. AbbVie Recent Development
    Table 158. Bayer Hlthcare Company Detail
    Table 159. Bayer Hlthcare Business Overview
    Table 160. Bayer Hlthcare New Molecular Entity (NME) Drug Product
    Table 161. Bayer Hlthcare Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 162. Bayer Hlthcare Recent Development
    Table 163. Sanofi Company Detail
    Table 164. Sanofi Business Overview
    Table 165. Sanofi New Molecular Entity (NME) Drug Product
    Table 166. Sanofi Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 167. Sanofi Recent Development
    Table 168. Immumnocore Company Detail
    Table 169. Immumnocore Business Overview
    Table 170. Immumnocore New Molecular Entity (NME) Drug Product
    Table 171. Immumnocore Revenue in New Molecular Entity (NME) Drug Business (2019-2024) & (US$ Million)
    Table 172. Immumnocore Recent Development
    Table 173. Research Programs/Design for This Report
    Table 174. Key Data Information from Secondary Sources
    Table 175. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global New Molecular Entity (NME) Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global New Molecular Entity (NME) Drug Market Share by Type: 2023 VS 2030
    Figure 3. Antibody Features
    Figure 4. Polypeptide Features
    Figure 5. Small Molecule Drug Features
    Figure 6. Other Features
    Figure 7. Global New Molecular Entity (NME) Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global New Molecular Entity (NME) Drug Market Share by Application: 2023 VS 2030
    Figure 9. Hospital Case Studies
    Figure 10. Clinic Case Studies
    Figure 11. New Molecular Entity (NME) Drug Report Years Considered
    Figure 12. Global New Molecular Entity (NME) Drug Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global New Molecular Entity (NME) Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global New Molecular Entity (NME) Drug Market Share by Region: 2023 VS 2030
    Figure 15. Global New Molecular Entity (NME) Drug Market Share by Players in 2023
    Figure 16. Global Top New Molecular Entity (NME) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in New Molecular Entity (NME) Drug as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by New Molecular Entity (NME) Drug Revenue in 2023
    Figure 18. North America New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America New Molecular Entity (NME) Drug Market Share by Country (2019-2030)
    Figure 20. United States New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Canada New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe New Molecular Entity (NME) Drug Market Share by Country (2019-2030)
    Figure 24. Germany New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. France New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. U.K. New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Italy New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Russia New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Nordic Countries New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Asia-Pacific New Molecular Entity (NME) Drug Market Share by Region (2019-2030)
    Figure 32. China New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Japan New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. South Korea New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Southeast Asia New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. India New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Australia New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Latin America New Molecular Entity (NME) Drug Market Share by Country (2019-2030)
    Figure 40. Mexico New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Brazil New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Middle East & Africa New Molecular Entity (NME) Drug Market Share by Country (2019-2030)
    Figure 44. Turkey New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Saudi Arabia New Molecular Entity (NME) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. UCB Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 47. Otsuka Pharmaceutical Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 48. Eli Lilly Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 49. Genentech Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 50. Eisai Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 51. Biogen Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 52. Menarini Group Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 53. GSK Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 54. Chest Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 55. Travere Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 56. Reata Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 57. Pfizer Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 58. Acadia Pharmaceuticals Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 59. Incyte Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 60. Cidara Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 61. Melinta Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 62. Pharming Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 63. LEO Pharma Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 64. Novartis Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 65. Argenx Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 66. Takeda Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 67. AbbVie Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 68. Bayer Hlthcare Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 69. Sanofi Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 70. Immumnocore Revenue Growth Rate in New Molecular Entity (NME) Drug Business (2019-2024)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Stainless Steel Medication Trolley Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-18N15820
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Instant Molecular Testing Service Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-33G15638
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Universal Cell Therapy Drug Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14U15769
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Global Preclinical Toxicology Testing Service Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-1P15930
Wed Aug 28 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions